Licensed RNAi Product definition

Licensed RNAi Product means an RNAi Product, the identification, characterization, validation, synthesis, development, use, formulation, manufacture, production or sale of which would infringe a Valid Claim but for the grant of the licenses set forth in this Agreement.
View Source
Licensed RNAi Product means a pharmaceutical product (a) containing, comprised or based on siRNAs or siRNA derivatives or other moieties effective in gene function modulation and designed to modulate the function of the Target through RNA interference and (b) incorporating DPC Technology.
View Source
Licensed RNAi Product means (a) with respect to PROTIVA and its Affiliates and Sublicensees, an RNAi Product, the identification, characterization, validation, synthesis, development, use, formulation, manufacture, production or sale of which, where and when occurring, would, but for the grant of a license or sublicense from Alnylam, infringe a Valid Claim of the Alnylam Patent Rights; and (b) with respect to Alnylam and its Affiliates and Sublicensees, an RNAi Product, the identification, characterization, validation, synthesis, development, use, formulation, manufacture, production or sale of which, where and when occurring, would, but for the grant of a license or sublicense from PROTIVA, infringe a Valid Claim of the PROTIVA Patent Rights.
View Source

Examples of Licensed RNAi Product in a sentence

  • Milestone payments will be due only once for the first RNAi Product against the Target being developed by QUARK, or an Affiliate or Sublicensee of QUARK, to achieve the relevant milestone event that is a Licensed RNAi Product or would be a Licensed RNAi Product if all of the claims included in the patent applications under ALNYLAM Patent Rights in existence in Major Market countries as of the date such milestone event is achieved were to issue in their then-current form.

  • Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including without limitation the obligation to pay royalties for Licensed RNAi Product sold prior to such expiration or termination.

  • Until the First Commercial Sale of a Licensed RNAi Product, QUARK will pay to ALNYLAM an annual maintenance fee in the amount of [ * ] for the license granted under this Agreement.

  • Products/Clinical/Professional Liability, exclusive of the coverage provided by the Comprehensive General Liability policy, with an aggregate limit of at least [ * ] with ALNYLAM to be named as an additional insured party with respect to each Licensed RNAi Product under such coverage.

  • As used herein, the term “Generic Product” means any pharmaceutical product sold by a third party, not authorized by QUARK or any Affiliate or Sublicensee, that contains the same active pharmaceutical ingredient as a Licensed RNAi Product and is approved in reliance on the prior approval of a Licensed RNAi Product as determined by the applicable regulatory authority.

  • Initiation of first Clinical Trial $ *** Dosing of the first patient in a Pivotal Trial $ *** First Approval granted by a Regulatory Authority $ *** First Commercial Sale of a Licensed RNAi Product $ *** In the event one or more milestone events set out above are skipped for any reason, the payment for such skipped milestone events(s) will be due upon the earlier of (a) achievement of the next achieved milestone event or (b) First Commercial Sale of a Licensed RNAi Product.

  • Milestone payments will be due only once for the first Licensed RNAi Product to achieve the relevant milestone event and not for any subsequent Licensed RNAi Product or second generation of the same.

  • Upon the achievement by ARROWHEAD, its Affiliates or Sublicensees of each of the milestone events in the table below with respect to a Licensed RNAi Product, ARROWHEAD will provide written notice to ALNYLAM of the occurrence of such milestone event within five (5) days after such event and ARROWHEAD will make the indicated milestone payment to ALNYLAM within thirty (30) days after the occurrence of such event.

  • During the Term, neither ALNYLAM nor any of its Affiliates shall, directly or indirectly, Develop, manufacture commercial quantities of or Commercialize, any Licensed RNAi Product in the Field in the Territory, or collaborate with or assist any Third Party with respect to any of the foregoing, except as provided in this Agreement.

  • At any time during the Research Collaboration Term but prior the start of the first study of a Licensed RNAi Product in a non-rodent efficacy animal model, ARROWHEAD may provide ALNYLAM written notice designating one (1) alternative target that ARROWHEAD desires to Research, Develop and Commercialize in accordance with this Agreement.